To: CAHAN San Diego Participants  
Date: February 25, 2022  
From: Public Health Services

Health Advisory Update #50: Coronavirus Disease 2019 (COVID-19) Vaccine Updates

Key Messages

- On February 11, 2022, the Centers for Disease Control and Prevention (CDC) updated the recommendations on the COVID-19 Interim Clinical Considerations for the Use of COVID-19 Vaccines webpage.
- Moderately to severely immunocompromised individuals are now eligible to receive a booster dose 3 months after completing their primary series.
- Moderately to severely immunocompromised individuals who received the Janssen/J&J primary series and Janssen booster are eligible to receive a 3rd full dose of an mRNA vaccine 3 months after their last Janssen dose.
- COVID-19 vaccination should no longer be delayed following administration of passive antibody products.
- The CDC has developed a quick reference of persons requiring COVID-19 vaccination following initial doses outside the United States.
- A history of myocarditis or pericarditis after an mRNA COVID-19 vaccine was added as a precaution for subsequent doses.
- COVID-19 vaccination doses can be administered without delay following recovery from COVID-19 infection and completion of required isolation.

Situation

On February 11, 2022, the Centers for Disease Control and Prevention (CDC) updated the COVID-19 Interim Clinical Considerations for Use of COVID-19 Vaccines recommendations on additional doses in primary series and timing of boosters for persons with immune compromised (including primary and secondary or acquired immune deficiencies). This update incorporates the Advisory Committee on Immunization Practices’ (ACIP) recommendation of December 16, 2021, for preference for mRNA vaccines over the viral vector (Janssen/J&J) vaccine. In addition, CDC simplified vaccination following receipt of passive antibody treatments for COVID-19, clarified instructions for persons vaccinated outside the U.S., and added pericarditis/myocarditis following COVID-19 as a precaution.

Background

Vaccines for the Immune Compromised

All individuals with moderately to severely immunocompromising conditions should receive an additional dose after their COVID-19 primary series and a booster 3 months after completion of their primary series and additional dose (Table 1).

- Individuals who received two doses of an mRNA (Pfizer or Moderna) vaccine, should receive an additional 3rd (full) dose of an mRNA vaccine 28 days after the 2nd dose. These individuals are now eligible for a booster dose at 3 months (instead of 5 months) after the 3rd dose.
- Individuals who received the one dose Janssen/J&J viral vector primary series should receive an additional 2nd (full) dose of an mRNA (Pfizer or Moderna) vaccine is recommended 28 days after the Janssen vaccine.
• Individuals who received the single dose Janssen/J&J viral vector primary series and a Janssen booster dose should receive an additional (full) dose of an mRNA (Pfizer or Moderna) vaccine 28 days after the Janssen booster.

Since only the Pfizer vaccine is authorized for use in children < 18 years of age, children 5–17 years of age with moderately to severely immunocompromising conditions should receive an additional, age-appropriate 3rd dose of Pfizer vaccine as part of the primary series. However, at this time, only children 12–17 years of age are authorized to receive a Pfizer booster (4th) dose 3 months after completing the primary Pfizer series.

Table 1. COVID-19 vaccine dosing/intervals for moderately to severely immunocompromised persons.

<table>
<thead>
<tr>
<th>Primary vaccination</th>
<th>Age group, years</th>
<th>Number of primary and/or additional vaccine doses</th>
<th>Number of booster doses</th>
<th>Interval between 1st and 2nd dose</th>
<th>Interval between 2nd and 3rd dose</th>
<th>Interval between 3rd and 4th dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>5–11</td>
<td>3</td>
<td>N/A</td>
<td>21 days</td>
<td>≥28 days</td>
<td>N/A</td>
</tr>
<tr>
<td>Pfizer</td>
<td>&gt;12</td>
<td>3</td>
<td>1</td>
<td>21 days</td>
<td>≥28 days</td>
<td>≥3 months</td>
</tr>
<tr>
<td>Moderna</td>
<td>≥18</td>
<td>3</td>
<td>1</td>
<td>28 days</td>
<td>≥28 days</td>
<td>≥3 months</td>
</tr>
<tr>
<td>Janssen/J&amp;J</td>
<td>≥18</td>
<td>2 (Janssen + mRNA)</td>
<td>1 (mRNA)</td>
<td>≥28 days</td>
<td>≥2 months</td>
<td>N/A</td>
</tr>
<tr>
<td>Janssen/J&amp;J</td>
<td>≥18</td>
<td>2 (Janssen prime and booster)</td>
<td>1 (full dose mRNA*)</td>
<td>≥2 months</td>
<td>≥2 months</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* The dose for Moderna vaccine should be the full 0.5 mL not 0.25mL booster dose (Guidance for People who are Moderately or Severely Immunocompromised and Vaccinated with Janssen COVID-19 Vaccine).

**Vaccine for Recipients of Passive Antibody Products**

The CDC has simplified recommendations on vaccination following the receipt of passive COVID-19 antibody products (e.g., monoclonal antibody (mAb) products, convalescent sera): COVID-19 vaccine doses (primary and booster) can be given without delay. Previously, a 90-day deferral was recommended. However, there is a 2-week deferral period following COVID-19 vaccination for persons to receive Evusheld (tixagevimab with cilgavimab).

**Persons Vaccinated Outside the United States**

The CDC developed a quick reference for vaccination of persons who have already received doses of COVID-19 vaccine outside the United States (People who received COVID-19 vaccine outside the United States).

**Subsequent COVID-19 Vaccine Doses Following Myocarditis or Pericarditis**

The CDC has updated the contraindication and precaution section to include a history of myocarditis or pericarditis after an mRNA COVID-19 vaccine as a precaution for subsequent doses of any COVID-19 vaccination. Until additional safety data are available, subsequent doses of any COVID-19 vaccine should generally be avoided. If after a risk assessment, a subsequent COVID-19 vaccine dose is considered, delay until after the episode of myocarditis or pericarditis has resolved. For those eligible, Janssen/J&J COVID-19 vaccine may be considered instead of mRNA COVID-19 vaccine.

**Vaccine for Persons Recently Recovered from COVID-19**

As a reminder, COVID-19 vaccination (primary series doses and boosters) can be administered as soon as a person has recovered from COVID-19, provided the person is no longer required to isolate.

**Actions Requested**

1. If not already enrolled, providers can listen to the recorded webinar on how to enroll in the California COVID-19 vaccination program and participate in COVID-19 vaccination.
2. Remain up-to-date on COVID-19 vaccine clinical considerations:
   • Vaccinate moderately to severely immune compromised persons according to CDC recommendations for additional doses and shortened boosting intervals.
   • Do not delay vaccination of person who have recently recovered from COVID-19 infection.
   • Do not delay vaccination of persons who recently received COVID-19 passive antibody products.
3. Report vaccine-related adverse events and deaths, as well as vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS), and to the County Immunization Program at IZINFO.HHS@sdcounty.ca.gov or Fax: (619) 692-5677.

Resources
• COVID-19 Vaccines for Moderately or Severely Immunocompromised People | CDC
• Evusheld Fact Sheet for Healthcare Providers | FDA
• Sotrovimab Fact Sheet for Healthcare Providers | FDA

Thank you for your participation.

CAHAN San Diego
County of San Diego Health & Human Services Agency
Epidemiology and Immunization Services Branch
Phone: (619) 692-8499; Fax: (858) 715-6458
Urgent Phone for pm/weekends/holidays: (858) 565-5255
E-mail: cahan@sdcounty.ca.gov
Secure Website: http://cahan.ca.gov
Public Website: http://www.cahansandiego.com